Sanofi France

Mr Eric Moussaud-Fergeau
Mr Eric Moussaud-Fergeau
Out-Licensing Business Development & Licensing 

Sanofi Group Germany

Dr Oliver Freichel
Head of Global CHC Business Development & Strategy 

SANOFI-AVENTI GROUP France

Mrs Laurence CASSARINO
Licensing-out Lead - Portfolio Enhancement & Maximisation Dpt 

Sanova Pharma GesmbH Austria

Mr Alexander Burstein
Head of business development 

Santen Germany

Dr Robert Bauer
Director, Business Development EMEA 

SBA Ltd United Kingdom

Specialties: Business Development, Licensing and Market Research support, Alliance Management and Customer Relations to the Biotech, Medtech, Pharmaceutical and Life Sciences Industries, and Start-Up Coaching.

www.linkedin.com/in/simon-bennett-0390796

1.  Looking for co-investment opportunities under TPI's i2020 Accelerator scheme: early-stage, seed round, small molecule focus

2.  Looking for assets for licensing for clients, including: rare disease assets (except cell & gene therapy), CVD, pain management, respiratory, innovative technologies, 505(b)(2) products

3.  Meeting companies interested in state-of-the -art machine learning solutions for drug discovery

4.  Meeting companies interested in acquiring antibody libraries

5.  Meeting companies interested in acquiring a phase II ready asset in multiple myeloma

6.  Meeting companies interested in a range of market-ready nickel allergy products

Dr Simon Bennett
Dr Simon Bennett
Managing Director 

Sebela United States

Mr Jai Wall
VP 

SERVIER France

Dr Michel Sestier
Project Director Search Evaluation & Licensing Rheumatology / Oncology 
Mr Didier Landais
Global Head of Licensing 

Silence Therapeutics United Kingdom

Silence Therapeutics is a leading RNAi company, developing highly innovative medicines with life-saving potential for patients with serious and rare diseases, based upon its proprietary technology platform in GalNAc conjugated siRNA.

The Company is in a strong position to maximise the potential of its IP and technology through collaborations and the advancement of internal programmes toward the clinic. Silence’s lead candidate SLN124 will move into clinical development in the coming year.

Mr John Strafford
Business Development Director 
Dr Joana Santos
Competitive Intelligence Analyst 

Springer SBM B.V. Netherlands

Mr Lenerl Sharp
Lincensing Manager